CA2570386A1 - Methods of using albuterol and calcium activated potassium channel openers - Google Patents

Methods of using albuterol and calcium activated potassium channel openers Download PDF

Info

Publication number
CA2570386A1
CA2570386A1 CA002570386A CA2570386A CA2570386A1 CA 2570386 A1 CA2570386 A1 CA 2570386A1 CA 002570386 A CA002570386 A CA 002570386A CA 2570386 A CA2570386 A CA 2570386A CA 2570386 A1 CA2570386 A1 CA 2570386A1
Authority
CA
Canada
Prior art keywords
albuterol
potassium channel
pharmaceutically acceptable
solvate
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002570386A
Other languages
English (en)
French (fr)
Inventor
Timothy J. Barberich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2570386A1 publication Critical patent/CA2570386A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002570386A 2004-06-14 2005-06-14 Methods of using albuterol and calcium activated potassium channel openers Abandoned CA2570386A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US57882704P 2004-06-14 2004-06-14
US60/578,827 2004-06-14
US59902704P 2004-08-06 2004-08-06
US60/599,027 2004-08-06
US60729004P 2004-09-07 2004-09-07
US60/607,290 2004-09-07
PCT/US2005/021171 WO2005123071A1 (en) 2004-06-14 2005-06-14 Methods of using albuterol and calcium activated potassium channel openers

Publications (1)

Publication Number Publication Date
CA2570386A1 true CA2570386A1 (en) 2005-12-29

Family

ID=35509445

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002570386A Abandoned CA2570386A1 (en) 2004-06-14 2005-06-14 Methods of using albuterol and calcium activated potassium channel openers

Country Status (6)

Country Link
US (1) US20090035224A1 (https=)
EP (1) EP1773325A4 (https=)
JP (1) JP2008502698A (https=)
AU (1) AU2005254096A1 (https=)
CA (1) CA2570386A1 (https=)
WO (1) WO2005123071A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1634595T3 (pl) * 2004-08-19 2009-01-30 Rottapharm Spa Pochodne N-fenylobenzamidu jako leki do leczenia COPD
WO2007077164A1 (en) * 2006-01-06 2007-07-12 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and andolast
PT2054057E (pt) 2006-07-31 2011-05-05 Rottapharm Spa Combina??o de andolast/glucocortic?ides
JP6211380B2 (ja) * 2012-10-17 2017-10-11 丸善製薬株式会社 Ｔｉｅ２活性化剤、血管新生抑制剤、血管の成熟化剤、血管の正常化剤、及び血管の安定化剤
JP2013056925A (ja) * 2012-11-21 2013-03-28 Rottapharm Spa アンドラスト／グルココルチコイドの併用
CN112535668B (zh) * 2020-10-29 2023-08-18 苏州君宁新药开发中心有限公司 一种左旋硫酸沙丁胺醇颗粒剂及其用途
CN113476428B (zh) * 2021-01-28 2022-03-29 朗天药业(湖北)有限公司 一种吸入用硫酸沙丁胺醇溶液及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69118359T2 (de) * 1990-01-05 1996-08-14 Sepracor,Inc., Marlborough, Ma. Optisch reines r(-)albuterol zur behandlung von asthma
US5200422A (en) * 1990-09-24 1993-04-06 Neurosearch A/S Benzimidazole derivatives, their preparation and use
US5637470A (en) * 1994-05-13 1997-06-10 Merck & Co., Inc. Screening array using cells expressing recombinant α and β subunits of the mammalian large-conductance (maxi-K) potassium channel
ATE241980T1 (de) * 1997-08-08 2003-06-15 Rotta Research Lab Neue inhalationspräparate enthaltend cr 2039 (andolast)
JP2002523452A (ja) * 1998-08-26 2002-07-30 スミスクライン・ビーチャム・コーポレイション 肺疾患の治療方法
US6656461B1 (en) * 2000-02-29 2003-12-02 The Trustees Of Columbia University In The City Of New York Therapeutic treatment of chronic obstructive pulmonary disease
US7713964B2 (en) * 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
TWI271402B (en) * 2002-10-15 2007-01-21 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof

Also Published As

Publication number Publication date
EP1773325A4 (en) 2007-11-07
JP2008502698A (ja) 2008-01-31
AU2005254096A1 (en) 2005-12-29
US20090035224A1 (en) 2009-02-05
WO2005123071A1 (en) 2005-12-29
EP1773325A1 (en) 2007-04-18

Similar Documents

Publication Publication Date Title
US20150209311A1 (en) (r,r) formoterol in combination with other pharmacological agents
US20030013740A1 (en) Stable dosage forms of fluoxetine and its enantiomers
US20080293788A1 (en) Methods and Compositions for the Treatment of Pulmonary Diseases
US20090035224A1 (en) Methods of Using Albuterol and Calcium Activated Potassium Channel Openers
US20070167496A1 (en) Roflumilast and glycopyrronium combination
WO2021194446A1 (en) A sachet formulation comprising metformin and dapagliflozin
US20020173522A1 (en) Pharmaceutical compositions comprising norastemizole
AU2005254101A1 (en) Methods and compositions for the treatment of pulmonary diseases
US20050228052A1 (en) Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine
RU2214245C2 (ru) Химически- и термостабильные готовые формы норастемизола
AU2011236040A1 (en) (R,R)-Formoterol in combination with other pharmacological agents
AU735257C (en) Chemically and thermally stable norastemizole formulations
US20240082176A1 (en) Dropropizine in combination with ambroxol in the dosage form of syrup and tablets
TR201612324A1 (tr) Solunum Yolu Hastalıklarında Kullanılan Farmasötik Terkipler
TR201611685A1 (tr) Oral farmasöti̇k terki̇pler
HK1027963A (en) Chemically and thermally stable norastemizole formulations

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20110614